Health Catalyst Divests Vitalware Business for $147 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Strategic Focus: Health Catalyst has signed a definitive agreement to divest its Vitalware business to Med-Metrix for $147 million in cash, which sharpens the company's focus on enhancing health systems' cost, clinical, and consumer performance, and is expected to accelerate its ongoing transformation.
- Increased Financial Flexibility: The transaction is anticipated to strengthen Health Catalyst's balance sheet, providing greater financial flexibility to prioritize investments in core technology and AI, thereby supporting its long-term strategy.
- Debt Repayment Plan: The company plans to use the net proceeds from the divestiture, along with cash on hand, to fully repay approximately $160 million of its senior secured term loan, reducing financial burdens and optimizing its capital structure.
- Vitalware's Market Position: Vitalware, a leading revenue cycle management software provider with approximately $37 million in revenue for fiscal year 2025, will benefit from Med-Metrix's acquisition, which positions it for deeper investment and development opportunities, further solidifying its leadership in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCAT
Wall Street analysts forecast HCAT stock price to rise
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 1.940
Low
2.75
Averages
3.85
High
5.00
Current: 1.940
Low
2.75
Averages
3.85
High
5.00
About HCAT
Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Med-Metrix Acquires Vitalware to Enhance Technology Platform
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware from Health Catalyst, which is expected to enhance Med-Metrix's technology platform and improve reimbursement accuracy and net revenue yield for its clients.
- Integration Benefits: The leadership team and employees of Vitalware will be integrated into Med-Metrix's operations, enhancing the company's ability to deliver end-to-end revenue cycle management solutions by combining differentiated technology with operational expertise.
- Industry Impact: Founded in 2011, Vitalware's cloud-based solutions have been widely adopted across hospitals and health systems, improving visibility and continuity in billing and coding processes, thereby enhancing client satisfaction.
- Financial Outcome Expectations: Med-Metrix executives highlighted that the acquisition will help providers identify revenue leakage, strengthen compliance, and optimize net patient revenue, further enhancing the company's competitive position in the healthcare revenue cycle management sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Overview: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leader in revenue workflow and analytics software owned by Health Catalyst, which is expected to significantly enhance Med-Metrix's mid-revenue cycle capabilities and improve net revenue yield for its clients.
- Technological Integration Benefits: Vitalware's cloud-based solutions excel in chargemaster management, revenue integrity, and coding workflows, and by integrating this technology, Med-Metrix will better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership team and employees will be integrated into Med-Metrix's operations, which will not only enhance the company's operational capabilities but also improve its ability to deliver end-to-end solutions, driving further business growth.
- Strategic Investment Context: Supported by Harvest Partners and A&M Capital Partners, this acquisition reflects confidence in Med-Metrix's future growth strategy, with Vitalware's addition providing stronger market competitiveness and technological support to aid its continued expansion in the healthcare services sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leading revenue workflow and analytics software provider owned by Health Catalyst, which is expected to enhance Med-Metrix's mid-revenue cycle capabilities, improving charge capture and coding accuracy, thereby significantly boosting net revenue yield for clients.
- Technology Integration: Vitalware's cloud-based solutions excel in critical functions such as chargemaster management and revenue integrity, and their integration will enable Med-Metrix to better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership and employees will be integrated into Med-Metrix's operations, which not only enhances the company's ability to deliver end-to-end solutions but also drives sustained growth in revenue management.
- Strategic Investment Support: Harvest Partners is backing this acquisition, and the addition of Vitalware will enhance Med-Metrix's mid-revenue cycle capabilities, further propelling the company's strategy of executing growth through both organic initiatives and targeted acquisitions.
See More
Health Catalyst Sells Vitalware for $147 Million
- Transaction Value: Health Catalyst has signed a definitive agreement to divest Vitalware and its business unit to Med-Metrix for $147 million in cash, which is expected to significantly enhance the company's financial flexibility and support its core technology and AI investments.
- Stock Price Reaction: Following the announcement of the transaction, Health Catalyst's shares rose by 33% in premarket trading, reflecting the market's positive response and optimistic outlook on the company's future financial health.
- Debt Repayment Plan: The company plans to use the net proceeds from the sale, combined with cash on hand, to fully repay approximately $160 million of outstanding principal on its senior secured term loan, further optimizing its capital structure and reducing financial costs.
- Transaction Timeline: The transaction is expected to close this year, marking a significant step for Health Catalyst in optimizing its asset portfolio and focusing on core business, potentially laying the groundwork for future growth.
See More
Health Catalyst Divests Vitalware Business for $147 Million
- Strategic Focus: Health Catalyst has signed a definitive agreement to divest its Vitalware business to Med-Metrix for $147 million in cash, which sharpens the company's focus on enhancing health systems' cost, clinical, and consumer performance, and is expected to accelerate its ongoing transformation.
- Increased Financial Flexibility: The transaction is anticipated to strengthen Health Catalyst's balance sheet, providing greater financial flexibility to prioritize investments in core technology and AI, thereby supporting its long-term strategy.
- Debt Repayment Plan: The company plans to use the net proceeds from the divestiture, along with cash on hand, to fully repay approximately $160 million of its senior secured term loan, reducing financial burdens and optimizing its capital structure.
- Vitalware's Market Position: Vitalware, a leading revenue cycle management software provider with approximately $37 million in revenue for fiscal year 2025, will benefit from Med-Metrix's acquisition, which positions it for deeper investment and development opportunities, further solidifying its leadership in the market.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Med-Metrix Acquires Vitalware to Enhance Technology Platform
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware from Health Catalyst, which is expected to enhance Med-Metrix's technology platform and improve reimbursement accuracy and net revenue yield for its clients.
- Integration Benefits: The leadership team and employees of Vitalware will be integrated into Med-Metrix's operations, enhancing the company's ability to deliver end-to-end revenue cycle management solutions by combining differentiated technology with operational expertise.
- Industry Impact: Founded in 2011, Vitalware's cloud-based solutions have been widely adopted across hospitals and health systems, improving visibility and continuity in billing and coding processes, thereby enhancing client satisfaction.
- Financial Outcome Expectations: Med-Metrix executives highlighted that the acquisition will help providers identify revenue leakage, strengthen compliance, and optimize net patient revenue, further enhancing the company's competitive position in the healthcare revenue cycle management sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Overview: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leader in revenue workflow and analytics software owned by Health Catalyst, which is expected to significantly enhance Med-Metrix's mid-revenue cycle capabilities and improve net revenue yield for its clients.
- Technological Integration Benefits: Vitalware's cloud-based solutions excel in chargemaster management, revenue integrity, and coding workflows, and by integrating this technology, Med-Metrix will better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership team and employees will be integrated into Med-Metrix's operations, which will not only enhance the company's operational capabilities but also improve its ability to deliver end-to-end solutions, driving further business growth.
- Strategic Investment Context: Supported by Harvest Partners and A&M Capital Partners, this acquisition reflects confidence in Med-Metrix's future growth strategy, with Vitalware's addition providing stronger market competitiveness and technological support to aid its continued expansion in the healthcare services sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leading revenue workflow and analytics software provider owned by Health Catalyst, which is expected to enhance Med-Metrix's mid-revenue cycle capabilities, improving charge capture and coding accuracy, thereby significantly boosting net revenue yield for clients.
- Technology Integration: Vitalware's cloud-based solutions excel in critical functions such as chargemaster management and revenue integrity, and their integration will enable Med-Metrix to better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership and employees will be integrated into Med-Metrix's operations, which not only enhances the company's ability to deliver end-to-end solutions but also drives sustained growth in revenue management.
- Strategic Investment Support: Harvest Partners is backing this acquisition, and the addition of Vitalware will enhance Med-Metrix's mid-revenue cycle capabilities, further propelling the company's strategy of executing growth through both organic initiatives and targeted acquisitions.
See More
Health Catalyst Sells Vitalware for $147 Million
- Transaction Value: Health Catalyst has signed a definitive agreement to divest Vitalware and its business unit to Med-Metrix for $147 million in cash, which is expected to significantly enhance the company's financial flexibility and support its core technology and AI investments.
- Stock Price Reaction: Following the announcement of the transaction, Health Catalyst's shares rose by 33% in premarket trading, reflecting the market's positive response and optimistic outlook on the company's future financial health.
- Debt Repayment Plan: The company plans to use the net proceeds from the sale, combined with cash on hand, to fully repay approximately $160 million of outstanding principal on its senior secured term loan, further optimizing its capital structure and reducing financial costs.
- Transaction Timeline: The transaction is expected to close this year, marking a significant step for Health Catalyst in optimizing its asset portfolio and focusing on core business, potentially laying the groundwork for future growth.
See More
Health Catalyst Divests Vitalware Business for $147 Million
- Strategic Focus: Health Catalyst has signed a definitive agreement to divest its Vitalware business to Med-Metrix for $147 million in cash, which sharpens the company's focus on enhancing health systems' cost, clinical, and consumer performance, and is expected to accelerate its ongoing transformation.
- Increased Financial Flexibility: The transaction is anticipated to strengthen Health Catalyst's balance sheet, providing greater financial flexibility to prioritize investments in core technology and AI, thereby supporting its long-term strategy.
- Debt Repayment Plan: The company plans to use the net proceeds from the divestiture, along with cash on hand, to fully repay approximately $160 million of its senior secured term loan, reducing financial burdens and optimizing its capital structure.
- Vitalware's Market Position: Vitalware, a leading revenue cycle management software provider with approximately $37 million in revenue for fiscal year 2025, will benefit from Med-Metrix's acquisition, which positions it for deeper investment and development opportunities, further solidifying its leadership in the market.
See More
